Publication
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (54)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 54
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugCetuximabcivic_curation1.00
- drugChemotherapycivic_curation1.00
- drugFluorouracilcivic_curation1.00
- drugIrinotecancivic_curation1.00
- drugOxaliplatincivic_curation1.00
- drugPanitumumabcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneKRAScivic_curation1.00
- geneNRAScivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantBRAF D594Gcivic_curation1.00
- variantBRAF Mutationcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantKRAS A146civic_curation1.00
- variantKRAS G12Acivic_curation1.00
- variantKRAS G12Ccivic_curation1.00
- variantKRAS G12Dcivic_curation1.00
- variantKRAS G12/G13civic_curation1.00
- variantKRAS G12Rcivic_curation1.00
- variantKRAS G12Scivic_curation1.00
- variantKRAS G12Vcivic_curation1.00
- variantKRAS G13Dcivic_curation1.00
- variantKRAS Mutationcivic_curation1.00
- variantKRAS Q61civic_curation1.00
- variantKRAS Q61Hcivic_curation1.00
- variantKRAS Q61Kcivic_curation1.00
- variantKRAS Q61Lcivic_curation1.00
- variantKRAS Q61Rcivic_curation1.00
- variantNRAS G12Ccivic_curation1.00
- variantNRAS G12Dcivic_curation1.00
- variantNRAS G13Rcivic_curation1.00
- variantNRAS Mutationcivic_curation1.00
- variantNRAS Q61civic_curation1.00
- variantNRAS Q61Hcivic_curation1.00
- variantNRAS Q61Kcivic_curation1.00
- variantNRAS Q61Lcivic_curation1.00
- variantNRAS Q61Rcivic_curation1.00
- variantPIK3CA C420Rcivic_curation1.00
- variantPIK3CA E542Kcivic_curation1.00
- variantPIK3CA E545Kcivic_curation1.00
- variantPIK3CA E545Qcivic_curation1.00
- variantPIK3CA E81Kcivic_curation1.00
- variantPIK3CA Exon 10 Mutationcivic_curation1.00
- variantPIK3CA Exon 21 Mutationcivic_curation1.00
- variantPIK3CA G1049Rcivic_curation1.00
- variantPIK3CA H1047Lcivic_curation1.00
- variantPIK3CA H1047Rcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPIK3CA N345Kcivic_curation1.00
- variantPIK3CA Q546Kcivic_curation1.00
- variantPIK3CA R88Qcivic_curation1.00
- variantPIK3CA R93Wcivic_curation1.00
- variantPIK3CA S158Lcivic_curation1.00
Curated evidence
Evidence citing this paper (52)
50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20619739
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA R93W1 | ||||||||
| Cetuximab + Fluorouracil + OxaliplatinCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID4467One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R93W, was wildtype for KRAS, BRAF and NRAS… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC | civic |
| PIK3CA S158L1 | ||||||||
| Cetuximab + IrinotecanCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID4463One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA S158L, was wildtype for KRAS, BRAF and NRA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC | civic |